U01AI146356
Cooperative Agreement
Overview
Grant Description
Epigenome editing technologies for treating diverse disease.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
North Carolina
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 293% from $400,411 to $1,571,669.
Duke University was awarded
Epigenome Editing Technologies for Treating Diverse Disease
Cooperative Agreement U01AI146356
worth $1,571,669
from the National Institute of Allergy and Infectious Diseases in July 2019 with work to be completed primarily in North Carolina United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Expanding the Human Genome Engineering Repertoire (U01 Clinical Trial Not Allowed).
Status
(Complete)
Last Modified 4/5/24
Period of Performance
7/8/19
Start Date
6/30/23
End Date
Funding Split
$1.6M
Federal Obligation
$0.0
Non-Federal Obligation
$1.6M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01AI146356
Transaction History
Modifications to U01AI146356
Additional Detail
Award ID FAIN
U01AI146356
SAI Number
U01AI146356-1804813943
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
TP7EK8DZV6N5
Awardee CAGE
4B478
Performance District
NC-90
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,584,434 | 100% |
Modified: 4/5/24